EditForce develops drugs and seeds by using nucleic acid manipulation technologies.
EditForce develops drugs and seeds by using nucleic acid (DNA/RNA) manipulation technologies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 26, 2021 | Series Unknown | ¥800M | 4 | Newton Biocapital | — | Detail |
Mar 1, 2019 | Series B | ¥870M | 6 | — | — | Detail |
Feb 3, 2016 | Seed | ¥175M | 2 | UTEC - The University of Tokyo Edge Capital Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Newton Biocapital | Yes | Series Unknown |
Global Brain Corporation | — | Series Unknown |
ITOCHU Technology Ventures | — | Series Unknown |
UTEC - The University of Tokyo Edge Capital Partners | — | Series Unknown |
Japan Science and Technology Agency | — | Series B |
K4 Ventures | — | Series B |
QB Capital | — | Series B |
KISCO | — | Seed |